SOCRA CCRP Certification Exam — Questions and Answers

Question 1: What is 'research misconduct' in the context of clinical trials?

Any GCP violation noted on an FDA inspection
Fabrication, falsification, or plagiarism in conducting or reporting research (Correct answer)
Failure to meet enrollment targets
Any protocol deviation regardless of intent

Correct answer: Fabrication, falsification, or plagiarism in conducting or reporting research

Research misconduct is defined as fabrication (making up data), falsification (manipulating data), or plagiarism (using others' work without credit) in conducting or reporting research.

Question 2: What is the purpose of a trial master file (TMF)?

To track site budget and payments
To maintain the essential documents that allow reconstruction and evaluation of the trial conduct (Correct answer)
To store patient medical histories
To file FDA submission documents only

Correct answer: To maintain the essential documents that allow reconstruction and evaluation of the trial conduct

The TMF is the collection of essential documents that individually and collectively permit evaluation of the conduct of the trial and the quality of the data produced.

Question 3: What is a 'delegation log' (also called a 'delegation of authority log') at a clinical trial site?

A record of IRB meeting attendance
A record of sponsor payments to the site
A log of protocol deviations delegated to subinvestigators
A document identifying each staff member's qualifications and the specific trial tasks they are authorized to perform (Correct answer)

Correct answer: A document identifying each staff member's qualifications and the specific trial tasks they are authorized to perform

A delegation log records each study team member's qualifications (CV, training) and the specific tasks they are authorized to perform, signed by the PI.

Question 4: What is the primary purpose of maintaining a Trial Master File (TMF) in a clinical trial?

To manage the study budget
To store investigator CVs only
To track patient enrollment numbers
To provide documented evidence of trial conduct and regulatory compliance (Correct answer)

Correct answer: To provide documented evidence of trial conduct and regulatory compliance

The TMF serves as the definitive collection of essential documents that provides documented evidence that the clinical trial was conducted in accordance with GCP, applicable regulations, and the protocol.

Question 5: What is the role of a legally acceptable representative (LAR) in the informed consent process?

To provide informed consent on behalf of a subject who is unable to provide consent themselves (Correct answer)
To replace the subject entirely in making treatment decisions
To verify the accuracy of the case report forms
To serve as the study monitor

Correct answer: To provide informed consent on behalf of a subject who is unable to provide consent themselves

A legally acceptable representative may provide informed consent on behalf of a subject who is unable to do so (e.g., due to incapacity, age), according to applicable laws and regulations.

Question 6: What is a MedDRA in the context of adverse event reporting?

A medication dosage reference application
Medical Dictionary for Regulatory Activities — a standardized medical terminology for AE coding (Correct answer)
Medical Data Records Administration
A medical device regulatory approval process

Correct answer: Medical Dictionary for Regulatory Activities — a standardized medical terminology for AE coding

MedDRA (Medical Dictionary for Regulatory Activities) is the internationally standardized medical terminology used to classify and code adverse events in clinical trials.

Question 7: In a multi-site clinical trial, which document typically specifies how investigational product will be allocated and distributed to each participating site?

The site's standard operating procedures
The IRB approval letter for each site
The IP Management Plan or drug supply plan provided by the sponsor (Correct answer)
The principal investigator's curriculum vitae

Correct answer: The IP Management Plan or drug supply plan provided by the sponsor

The sponsor's IP Management Plan or drug supply plan outlines allocation, shipping, handling, and management of IP across all participating sites.

Question 8: What does 'subject screening' involve in clinical trial site management?

Evaluating potential participants against inclusion/exclusion criteria before enrolling them in the trial (Correct answer)
Selecting subjects from a published database
Conducting a background check on potential participants
Screening subjects for willingness to pay study costs

Correct answer: Evaluating potential participants against inclusion/exclusion criteria before enrolling them in the trial

Subject screening involves assessing candidates against the protocol's inclusion and exclusion criteria, typically including medical history review, physical exams, and lab tests.

Question 9: Which U.S. federal regulation specifically governs the labeling requirements for investigational new drugs (INDs)?

21 CFR Part 50
21 CFR Part 312 (Correct answer)
21 CFR Part 11
21 CFR Part 56

Correct answer: 21 CFR Part 312

21 CFR Part 312 governs the IND application process in the US, including labeling requirements for investigational new drugs used in clinical trials.

Question 10: Which of the following patients is unable to give informed consent?

An individual with full legal capacity
A competent adult
A patient who fully understands the risks and benefits
A child without parental guidance (Correct answer)

Correct answer: A child without parental guidance

Informed consent requires that an individual has the legal and mental capacity to understand the information presented and make a voluntary decision. A child, by legal definition, typically lacks the legal capacity to provide informed consent for medical procedures or research without the consent of a parent or legal guardian. This is due to their age and presumed inability to fully grasp complex medical information and its implications.

Question 11: What is a 'follow-up report' in the context of adverse event reporting?

A routine scheduled safety report
An updated report submitted when new information about a previously reported SAE becomes available (Correct answer)
The final summary of all AEs at the end of the trial
A report submitted after a DSMB meeting

Correct answer: An updated report submitted when new information about a previously reported SAE becomes available

A follow-up report is submitted when new information (such as outcome, additional lab results, or revised causality) becomes available for a previously reported expedited SAE.

Question 12: A CRC discovers that a subject was accidentally dispensed another subject's investigational product. What is the priority FIRST step?

Immediately assess the affected subject's safety and document the error as a protocol deviation and potential adverse event (Correct answer)
Correct the dispensing record and continue the visit as normal
Instruct the subject to return the IP without further investigation or documentation
Notify the IRB and wait for written guidance before taking any action

Correct answer: Immediately assess the affected subject's safety and document the error as a protocol deviation and potential adverse event

The immediate safety of the affected subject is the priority; the dispensing error must be assessed for safety implications and documented as a protocol deviation.

Question 13: Which of the following is an example of an input port commonly found on modern monitors?

PS/2
USB-C
HDMI (Correct answer)
Ethernet

Correct answer: HDMI

HDMI (High-Definition Multimedia Interface) is a very common and widely used input port on modern monitors. It transmits both high-definition video and audio signals over a single cable, making it a standard for connecting computers, gaming consoles, and other media devices. USB-C can also carry video, but HDMI is primarily a dedicated video input.

Question 14: What is the Declaration of Helsinki and its significance in clinical research?

A WHO treaty governing drug manufacturing standards
A European regulatory directive for drug approvals
An FDA guidance document on IND submissions
A set of ethical principles for medical research involving human subjects published by the World Medical Association (Correct answer)

Correct answer: A set of ethical principles for medical research involving human subjects published by the World Medical Association

The Declaration of Helsinki is the WMA's statement of ethical principles guiding physicians and researchers in medical research involving human subjects worldwide.

Question 15: Which section of the Investigator's Brochure (IB) contains information about the known and potential risks of the investigational product?

Table of Contents
Physical, Chemical, and Pharmaceutical Properties
Introduction
Summary of Data and Guidance for the Investigator (Correct answer)

Correct answer: Summary of Data and Guidance for the Investigator

The Summary of Data and Guidance for the Investigator section provides an overall discussion of nonclinical and clinical data, including known and potential risks and anticipated adverse events to help the investigator manage subjects appropriately.

Question 16: What is an eCRF in clinical research?

An electronic clinical research file
An electronic compliance review form
An electronic conflict-of-interest reporting form
An electronic case report form used to collect study data (Correct answer)

Correct answer: An electronic case report form used to collect study data

An eCRF (electronic Case Report Form) is an electronic format for collecting and transmitting clinical trial data from the investigative site to the sponsor.

Question 17: What is an IRB's primary mandate in the US clinical research system?

To verify sponsor financial disclosures
To ensure protocol scientific validity only
To approve drug safety for marketing
To protect the rights, safety, and welfare of human research subjects (Correct answer)

Correct answer: To protect the rights, safety, and welfare of human research subjects

An IRB's primary mandate is to protect the rights, safety, and welfare of individuals who participate as subjects in research studies.

Question 18: What does 21 CFR Part 11 govern in clinical research?

Investigational drug labeling
Electronic records and electronic signatures (Correct answer)
IRB review procedures
Adverse event reporting timelines

Correct answer: Electronic records and electronic signatures

21 CFR Part 11 establishes FDA criteria under which electronic records and electronic signatures are considered trustworthy and equivalent to paper records.

Question 19: Which of the following statements about informed consent language is correct according to ICH-GCP?

Technical medical terminology should be used to demonstrate scientific rigor
The consent form should be written in language that is understandable to the subject or the subject's legally acceptable representative (Correct answer)
The consent form should be available only in English for standardization
Legal disclaimers must be prominently featured

Correct answer: The consent form should be written in language that is understandable to the subject or the subject's legally acceptable representative

ICH-GCP requires that the informed consent form be written in language that is non-technical and understandable to the subject or the subject's legally acceptable representative.

Question 20: Which section of the Code of Federal Regulations addresses IRB composition and review procedures?

21 CFR Part 56 (Correct answer)
21 CFR Part 312
21 CFR Part 11
21 CFR Part 50

Correct answer: 21 CFR Part 56

21 CFR Part 56 covers IRB regulations, including composition, functions, operations, and review criteria.

Question 21: Which CDISC standard is used for formatting clinical trial data for FDA regulatory submission?

CDISC ODM
CDASH
SDTM (Correct answer)
ADaM

Correct answer: SDTM

SDTM (Study Data Tabulation Model) is the CDISC standard format required by the FDA for submitting clinical trial tabulation datasets.

Question 22: What is the primary purpose of a study protocol?

To avoid conducting preliminary research
To reduce the number of study participants
To ensure the study is completed quickly
To outline the scientific rationale and research design (Correct answer)

Correct answer: To outline the scientific rationale and research design

The primary purpose of a study protocol is to serve as a comprehensive blueprint for a research study or clinical trial. It meticulously outlines the scientific rationale, objectives, detailed methodology, and statistical considerations. This ensures the study is conducted systematically, ethically, and with scientific rigor, providing a clear roadmap for all involved.

Question 23: What is the purpose of an Investigator's Brochure (IB) in adverse event management?

To guide the investigator in prescribing the drug
To provide marketing information about the drug
To serve as the reference document for assessing the expectedness of adverse reactions (Correct answer)
To list all enrolled subjects and their adverse events

Correct answer: To serve as the reference document for assessing the expectedness of adverse reactions

The IB summarizes the clinical and nonclinical data on the investigational product and serves as the reference for determining whether an adverse reaction is expected.

Question 24: What action should be taken if an investigational product lot is recalled by the sponsor during an ongoing clinical trial?

Immediately quarantine the recalled lot and follow sponsor instructions for return or destruction (Correct answer)
Continue using the recalled lot until the current supply is exhausted
Substitute the recalled lot with a commercially available equivalent
Inform subjects only if they specifically inquire about their treatment

Correct answer: Immediately quarantine the recalled lot and follow sponsor instructions for return or destruction

A recalled lot must be immediately quarantined and handled per sponsor recall instructions, with subject safety and accountability as the primary concerns.

Question 25: What is the primary purpose of source data verification (SDV) during a monitoring visit?

To verify the site's financial records
To train site staff on the protocol
To ensure that data recorded in the CRF accurately reflects the source documents (Correct answer)
To audit the sponsor's clinical database

Correct answer: To ensure that data recorded in the CRF accurately reflects the source documents

Source data verification is the process by which the monitor compares CRF entries against original source documents to ensure accuracy, completeness, and consistency of reported data.

Question 26: What is 'blinded data review' in clinical research?

A data review conducted by an independent auditor
Reviewing data without subject identifiers
Reviewing only placebo arm data
Reviewing and cleaning data before treatment allocation codes are revealed (Correct answer)

Correct answer: Reviewing and cleaning data before treatment allocation codes are revealed

Blinded data review involves reviewing and resolving data issues before breaking the randomization code to prevent bias in data cleaning decisions.

Question 27: How should the protocol address the handling of protocol deviations and violations?

Deviations are only addressed in the monitoring plan
The protocol should define procedures for documenting, reporting, and managing deviations, including criteria distinguishing major from minor deviations (Correct answer)
The protocol should state that deviations are acceptable if they improve outcomes
The protocol does not need to address deviations

Correct answer: The protocol should define procedures for documenting, reporting, and managing deviations, including criteria distinguishing major from minor deviations

The protocol should include clear procedures for identifying, documenting, reporting, and managing protocol deviations, including definitions and criteria for classifying deviations as major or minor and the process for corrective action.

Question 28: What is a 'conflict of interest' in clinical research, and why is it significant?

A situation where personal or financial interests could unduly influence research decisions, potentially compromising integrity (Correct answer)
When two sponsors fund the same study
When a site investigator is also the IRB chair — it is not significant
A disagreement between sponsor and investigator about protocol design

Correct answer: A situation where personal or financial interests could unduly influence research decisions, potentially compromising integrity

A conflict of interest occurs when personal, financial, or other interests could compromise research objectivity, potentially biasing outcomes or violating participant protections.

Question 29: What is investigational product (IP) accountability at a clinical trial site?

Tracking the cost of IP per subject
Documenting the receipt, storage, dispensing, use, and return/destruction of all investigational product (Correct answer)
Ensuring the IP is covered by the study insurance policy
Verifying that the IP is FDA-approved

Correct answer: Documenting the receipt, storage, dispensing, use, and return/destruction of all investigational product

IP accountability involves maintaining records of all investigational product received, stored, dispensed to each subject, and returned or destroyed, ensuring complete chain of custody.

Question 30: What is the correct procedure for correcting an error in source documentation?

Use correction fluid to cover the error and rewrite
Remove the page and replace with a corrected version
Draw a single line through the error, write the correction, initial, and date it (Correct answer)
Have the sponsor make all corrections

Correct answer: Draw a single line through the error, write the correction, initial, and date it

The proper method for correcting source documents is to draw a single line through the error so the original entry remains legible, write the correct entry, and add initials and date of the person making the correction.

Question 31: What is a 'data query' in clinical trial data management?

A sponsor's request for interim analysis
A request to enroll additional subjects
A question raised to resolve a discrepancy or missing data in the case report form (Correct answer)
A regulatory agency inquiry about the study

Correct answer: A question raised to resolve a discrepancy or missing data in the case report form

A data query is a formal request sent to site personnel to clarify, correct, or provide missing information identified during data review.

Question 32: What is the difference between triggered and routine monitoring visits?

Routine visits are scheduled per the monitoring plan; triggered visits are unscheduled visits prompted by specific concerns or events (Correct answer)
Routine visits are only for data collection while triggered visits are for regulatory inspections
Triggered visits are only conducted by auditors, not monitors
There is no difference; all visits are the same

Correct answer: Routine visits are scheduled per the monitoring plan; triggered visits are unscheduled visits prompted by specific concerns or events

Routine monitoring visits are pre-planned visits scheduled according to the monitoring plan, while triggered visits are unscheduled visits initiated in response to specific events such as safety signals, high deviation rates, or enrollment concerns.

Question 33: What must a site do when a protocol deviation occurs that increases risk to participants?

Continue without action if risk is minimal
Report it to the IRB and sponsor promptly (Correct answer)
Report it only in the final study report
Notify only the FDA within 30 days

Correct answer: Report it to the IRB and sponsor promptly

Protocol deviations that increase risk to participants must be reported promptly to both the IRB and the sponsor per GCP requirements.

Question 34: How should amendments to an approved protocol be handled according to GCP?

Implemented immediately without approval
Applied retroactively after the trial is complete
Submitted to the IRB/IEC for review and approval before implementation, except for safety changes (Correct answer)
Only documented internally by the sponsor

Correct answer: Submitted to the IRB/IEC for review and approval before implementation, except for safety changes

Protocol amendments must be submitted to and approved by the IRB/IEC before implementation. The only exception is when an amendment is necessary to eliminate an immediate hazard to trial subjects, in which case it may be implemented before approval but must be submitted promptly thereafter.

Question 35: What is the significance of the Tuskegee Syphilis Study in US research ethics history?

It revealed systemic exploitation of vulnerable subjects and led to major regulatory reform including the Belmont Report (Correct answer)
It showed the importance of randomized controlled trial design
It established the first IRB in the United States
It demonstrated the effectiveness of penicillin treatment

Correct answer: It revealed systemic exploitation of vulnerable subjects and led to major regulatory reform including the Belmont Report

The Tuskegee study's exploitation of Black Americans — withholding known treatment — directly prompted the National Research Act (1974) and the Belmont Report.

Question 36: Which foundational document established ethical principles for research involving human subjects after World War II?

Belmont Report
Common Rule
Declaration of Helsinki
Nuremberg Code (Correct answer)

Correct answer: Nuremberg Code

The Nuremberg Code (1947) was the first international document to establish ethical principles for research involving humans, developed in response to Nazi medical experiments.

Question 37: A sponsor submits an IND to the FDA. If the FDA does not respond within how many days, the sponsor may proceed with the trial?

30 days (Correct answer)
45 days
14 days
21 days

Correct answer: 30 days

If the FDA does not place the IND on clinical hold within 30 days of receipt, the sponsor may proceed with the proposed clinical investigation.

Question 38: Under FDA regulations, how long must an investigator retain clinical trial records after the investigation is discontinued or completed?

5 years
7 years
2 years
3 years (Correct answer)

Correct answer: 3 years

Per 21 CFR Part 312.62, records must be retained for 2 years following the date a marketing application is approved, or 2 years after the investigation is discontinued.

Question 39: What is the Common Terminology Criteria for Adverse Events (CTCAE) used for?

Classifying the causal relationship of AEs to study drug
Coding adverse events into MedDRA terms
Standardizing adverse event reporting timelines
Grading the severity of adverse events on a scale of 1 to 5 (Correct answer)

Correct answer: Grading the severity of adverse events on a scale of 1 to 5

CTCAE provides a standardized grading scale (Grade 1–5) for classifying the severity of adverse events, widely used in oncology trials.

Question 40: What is 'unmasking' or 'unblinding' in the context of SAE reporting?

Revealing the subject's treatment assignment to assess causality for an SAE (Correct answer)
Publishing SAE data before the trial ends
Conducting a safety review without the DSMB
Removing a subject's identifying information from the report

Correct answer: Revealing the subject's treatment assignment to assess causality for an SAE

Unblinding for an SAE involves revealing the subject's treatment assignment (active vs. placebo) to allow proper causality assessment while maintaining blind for others.

Question 41: What is the purpose of specifying stopping rules in a clinical trial protocol?

To set working hours for site staff
To define predetermined criteria for early termination of the trial based on safety concerns, futility, or overwhelming efficacy (Correct answer)
To establish the deadline for database lock
To determine when to stop recruiting at a single site

Correct answer: To define predetermined criteria for early termination of the trial based on safety concerns, futility, or overwhelming efficacy

Stopping rules are predetermined statistical or clinical criteria specified in the protocol that trigger early termination of the trial if subjects face unacceptable risk, the treatment shows overwhelming benefit, or the trial is unlikely to demonstrate a meaningful effect.

Question 42: What is a 'protocol amendment' and what is required when one is issued?

A change that only requires the PI's signature to implement
A formal revision to the study protocol that requires IRB review and approval before implementation (Correct answer)
An informal update communicated verbally to site staff
A change to the financial terms of the study contract

Correct answer: A formal revision to the study protocol that requires IRB review and approval before implementation

A protocol amendment is a formal written change to the protocol that must be submitted to and approved by the IRB, and updated with regulatory authorities, before implementation.

Question 43: What is a 'clinical hold' in the context of FDA regulations?

An FDA order to delay or suspend a clinical investigation (Correct answer)
A temporary halt due to site staffing issues
A pause in patient enrollment requested by the IRB
A sponsor-initiated pause for protocol amendments

Correct answer: An FDA order to delay or suspend a clinical investigation

A clinical hold is an FDA order to delay a proposed or suspend an ongoing clinical investigation based on safety or compliance concerns.

Question 44: When dispensing investigational product to a trial subject, which step is MOST critical to prevent medication errors?

Verifying the subject's insurance coverage before dispensing
Having the sponsor monitor present during every dispensing event
Confirming the subject's randomization number, scheduled visit, and prescribed dose against the protocol (Correct answer)
Using only electronic dispensing systems approved by the sponsor

Correct answer: Confirming the subject's randomization number, scheduled visit, and prescribed dose against the protocol

Verifying the randomization number, visit schedule, and dose against the protocol at each dispensing event prevents errors and ensures protocol compliance.

Question 45: What documentation is required when a subject provides oral consent but is physically unable to sign the written consent form?

The sponsor must provide a waiver of written consent
An impartial witness must attest to the subject's oral consent by signing and dating the form (Correct answer)
No documentation is needed beyond verbal agreement
A video recording replaces the written requirement

Correct answer: An impartial witness must attest to the subject's oral consent by signing and dating the form

When a subject can understand and consent verbally but cannot physically sign, an impartial witness must be present, verify the subject's oral consent, and sign and date the form on the subject's behalf.

Question 46: Under GCP, which of the following best describes a 'certified copy'?

A document stamped by the FDA
A verified copy that has the same information as the original and is confirmed by a dated signature (Correct answer)
A notarized photocopy of any document
An electronic backup of paper records

Correct answer: A verified copy that has the same information as the original and is confirmed by a dated signature

A certified copy is a copy verified to have the same information as the original, confirmed as such by a dated signature, and is acceptable in place of the original.

Question 47: Which US federal regulation governs the protection of human subjects in research conducted or supported by federal departments?

21 CFR Part 50
21 CFR Part 312
45 CFR Part 164
45 CFR Part 46 (Correct answer)

Correct answer: 45 CFR Part 46

45 CFR Part 46, known as the Common Rule, is the federal regulation governing protection of human subjects in federally funded research.

Question 48: What is a site initiation visit (SIV) and when does it occur?

A visit conducted after regulatory approval to train site staff and ensure readiness to enroll subjects (Correct answer)
A visit to close out the site at the end of the trial
A visit to assess site feasibility before the trial begins
A routine monitoring visit during the enrollment phase

Correct answer: A visit conducted after regulatory approval to train site staff and ensure readiness to enroll subjects

A site initiation visit occurs after all regulatory approvals are in place and before the first subject is enrolled. Its purpose is to train site staff, review the protocol, verify site readiness, and ensure all essential documents are in place.

Question 49: What does 'medical monitoring' of adverse events involve in a clinical trial?

Ongoing review of safety data by a qualified medical professional to detect safety signals (Correct answer)
Scheduling subject medical appointments
Monitoring drug storage temperatures
Auditing site medical records for accuracy

Correct answer: Ongoing review of safety data by a qualified medical professional to detect safety signals

Medical monitoring involves a sponsor's qualified medical professional continuously reviewing safety data to identify potential safety signals and protect participant safety.

Question 50: What does the term "resolution" refer to in a monitor?

The refresh rate of the monitor
The number of colors a monitor can display
The contrast ratio of the display
The number of pixels displayed on the screen (Correct answer)

Correct answer: The number of pixels displayed on the screen

In a monitor, 'resolution' refers to the number of distinct pixels displayed on the screen, typically expressed as width x height (e.g., 1920x1080). A higher resolution means more pixels, resulting in a sharper, more detailed image and the ability to display more content simultaneously. It directly impacts the clarity and crispness of the visual output.

Question 51: What is the minimum time a subject should be given to consider participating in a clinical trial before signing the informed consent?

30 minutes is the regulatory standard
1 week as mandated by ICH-GCP
24 hours is always required
There is no specific minimum time, but the subject must have sufficient time to consider participation (Correct answer)

Correct answer: There is no specific minimum time, but the subject must have sufficient time to consider participation

ICH-GCP does not specify a minimum waiting period but requires that the subject be given sufficient time and opportunity to inquire about details of the trial and to decide whether to participate.

Question 52: Under 21 CFR 312.32, what is the reporting timeframe for serious, unexpected AEs that are NOT fatal or life-threatening?

15 calendar days (Correct answer)
7 calendar days
45 calendar days
30 calendar days

Correct answer: 15 calendar days

Non-fatal, non-life-threatening unexpected serious adverse drug reactions must be reported to the FDA within 15 calendar days under 21 CFR 312.32.

Question 53: According to ICH GCP E6(R2), investigational products must be stored under conditions specified by:

FDA general pharmaceutical storage guidelines
The IRB approval letter
The sponsor's protocol and investigational product information (Correct answer)
The site's standard operating procedures

Correct answer: The sponsor's protocol and investigational product information

ICH GCP requires IP to be stored according to conditions specified by the sponsor in the protocol or in the IP information provided to the site.

Question 54: Which principle requires that clinical trial data be attributable, legible, contemporaneous, original, and accurate?

GLP principle
CDISC standard
ALCOA principle (Correct answer)
SMART principle

Correct answer: ALCOA principle

The ALCOA principle (Attributable, Legible, Contemporaneous, Original, Accurate) defines the fundamental data quality standards in GCP.

Question 55: What is a protocol synopsis and what information does it contain?

A condensed summary of the key elements of the full protocol including objectives, design, population, and endpoints (Correct answer)
The complete statistical analysis plan
A patient-facing summary of the trial
A legal contract between the sponsor and investigator

Correct answer: A condensed summary of the key elements of the full protocol including objectives, design, population, and endpoints

A protocol synopsis is a brief summary document that provides an overview of the main elements of the clinical trial protocol, including the study title, objectives, design, key inclusion/exclusion criteria, treatment arms, endpoints, and sample size.

Question 56: What is a 'site qualification visit' (SQV) and when does it occur?

A pre-study visit by the sponsor/CRO to assess whether a site meets the requirements to conduct the trial (Correct answer)
A visit after database lock to assess site data quality
An FDA inspection of the site
A training visit for new site staff mid-trial

Correct answer: A pre-study visit by the sponsor/CRO to assess whether a site meets the requirements to conduct the trial

An SQV is conducted before site selection to evaluate the investigator's qualifications, facilities, subject population, and capacity to conduct the specific study.

Question 57: What is a 'Sponsor-Investigator' in clinical research?

An individual who both initiates and conducts a clinical investigation (Correct answer)
A co-investigator designated by the sponsor
A pharmaceutical company employee running a site
An investigator who also receives sponsor funding

Correct answer: An individual who both initiates and conducts a clinical investigation

A Sponsor-Investigator is an individual who both initiates and conducts an investigation and under whose immediate direction an investigational drug is administered.

Question 58: What is the key distinction between a 'sponsor' and an 'investigator' under FDA regulations?

The sponsor initiates and oversees the trial; the investigator conducts it at the site (Correct answer)
The investigator is always a physician; the sponsor is always a company
They are interchangeable terms
The sponsor conducts the trial; the investigator funds it

Correct answer: The sponsor initiates and oversees the trial; the investigator conducts it at the site

Under 21 CFR Part 312, the sponsor initiates and takes responsibility for the investigation, while the investigator conducts it at a specific site.

Question 59: How is a 'Serious Adverse Event' (SAE) defined under ICH GCP?

Any adverse event that causes discomfort
Any untoward medical occurrence that results in death, is life-threatening, requires hospitalization, or causes disability (Correct answer)
Any adverse event considered related to the study drug
An event that causes a protocol deviation

Correct answer: Any untoward medical occurrence that results in death, is life-threatening, requires hospitalization, or causes disability

An SAE is defined as any adverse event that results in death, is life-threatening, requires inpatient hospitalization, results in persistent disability, or is a congenital anomaly.

Question 60: Under what circumstance is emergency unblinding of a subject's treatment assignment justified in a blinded clinical trial?

When knowledge of treatment is essential for the subject's medical management in a life-threatening emergency (Correct answer)
When the sponsor's monitor requests it for data clarification
When the IRB requests it during a routine audit
When the subject insists on knowing their treatment assignment

Correct answer: When knowledge of treatment is essential for the subject's medical management in a life-threatening emergency

Emergency unblinding is only justified when the investigator needs the treatment assignment to provide appropriate emergency medical care to the subject.

Question 61: What is the difference between 'on-site monitoring' and 'remote monitoring' in clinical trials?

On-site monitoring is conducted by the FDA; remote monitoring by the sponsor
On-site monitoring involves the monitor physically visiting the site; remote monitoring uses electronic systems to review data without a site visit (Correct answer)
They are the same process conducted at different times
Remote monitoring is only allowed for low-risk studies

Correct answer: On-site monitoring involves the monitor physically visiting the site; remote monitoring uses electronic systems to review data without a site visit

On-site monitoring involves a physical visit to verify source documents and observe site operations, while remote monitoring reviews data electronically without visiting the site.

Question 62: What should a monitor verify regarding informed consent during routine monitoring visits?

That subjects received monetary compensation for signing
Only that consent forms exist in the file
That consents are properly signed and dated, were obtained before any study procedures, and are the current IRB-approved version (Correct answer)
Only that the principal investigator signed the form

Correct answer: That consents are properly signed and dated, were obtained before any study procedures, and are the current IRB-approved version

The monitor must verify that each subject's consent form is the current IRB-approved version, properly signed and dated by both the subject and the consenting investigator, and that consent was obtained prior to any study-specific procedures.

Question 63: What is a 'pharmacy manual' and why is it used at clinical trial sites?

A reference for subinvestigators on drug dosing calculations
A manual listing all approved medications in the hospital formulary
A financial guide for billing investigational drugs to insurance
A document providing site pharmacy staff with instructions for IP storage, dispensing, handling, and accountability procedures (Correct answer)

Correct answer: A document providing site pharmacy staff with instructions for IP storage, dispensing, handling, and accountability procedures

A pharmacy manual provides study-specific instructions to pharmacists regarding IP storage conditions, reconstitution, dispensing procedures, and accountability requirements.

Question 64: What information must be included in the site's regulatory binder for each clinical trial?

Only the signed protocol and consent form
All essential documents listed in ICH-GCP Section 8 (Correct answer)
Only the investigator's curriculum vitae
Only financial disclosure forms

Correct answer: All essential documents listed in ICH-GCP Section 8

The regulatory binder must contain all essential documents as listed in ICH-GCP Section 8, including but not limited to the signed protocol, IRB/IEC approvals, CVs, financial disclosures, delegation logs, lab certifications, and correspondence.

Question 65: A Form FDA 1572 is required to be signed by which individual?

The IRB Chairperson
The Sponsor's Medical Monitor
The Principal Investigator (Correct answer)
The CRO Project Manager

Correct answer: The Principal Investigator

Form FDA 1572 is the Statement of Investigator that must be signed by the Principal Investigator, committing to GCP compliance.

Question 66: What must be verified during a site feasibility assessment?

Only the IRB turnaround time at that institution
Only the investigator's publishing record
Whether the site has previously enrolled in any trial
Site's patient population, staff qualifications, facilities, regulatory experience, and competing studies (Correct answer)

Correct answer: Site's patient population, staff qualifications, facilities, regulatory experience, and competing studies

Site feasibility assesses the available patient population, investigator and staff qualifications and experience, facilities, equipment, and competing workload.

Question 67: Under 21 CFR Part 50, which individuals are considered 'vulnerable' populations requiring additional protections?

Pregnant women, prisoners, and children (Correct answer)
Non-English speaking participants
Elderly individuals over 65
Employees of the sponsor

Correct answer: Pregnant women, prisoners, and children

21 CFR Part 50 subparts C and D provide additional protections for children and prisoners as vulnerable populations.

Question 68: What are the five criteria an IRB must consider when approving research involving human subjects?

Regulatory compliance, financial viability, scientific merit, ethical oversight, publication plan
Risks minimized, risks reasonable to benefits, equitable subject selection, informed consent obtained, data safety monitored (Correct answer)
Budget, timeline, sponsor reputation, site capacity, staff qualifications
FDA approval, institutional approval, staff training, equipment validation, protocol review

Correct answer: Risks minimized, risks reasonable to benefits, equitable subject selection, informed consent obtained, data safety monitored

IRBs must find that risks are minimized, risks are reasonable relative to benefits, subject selection is equitable, informed consent is obtained, and safety monitoring is adequate.

Question 69: What does 'equipoise' mean in clinical research ethics?

Balancing subject burden with research value
Equal randomization between treatment arms
Genuine uncertainty within the expert community about the comparative merits of study treatments (Correct answer)
Equal distribution of study benefits across sites

Correct answer: Genuine uncertainty within the expert community about the comparative merits of study treatments

Clinical equipoise is the state of genuine uncertainty in the clinical community about which treatment in a trial is superior, ethically justifying randomization.

Question 70: What information is REQUIRED on the label of an investigational product intended for use in a clinical trial?

The commercial brand name and standard dosing instructions
The subject's home address and insurance information
The investigator's personal contact number
A statement that it is for investigational use only, protocol identification, and storage conditions (Correct answer)

Correct answer: A statement that it is for investigational use only, protocol identification, and storage conditions

GCP and regulatory requirements mandate that IP labels include 'For Investigational Use Only,' protocol identification, and required storage conditions.

Question 71: What is the role of a Clinical Research Coordinator (CRC)?

To serve as the Principal Investigator for the trial
To coordinate day-to-day trial activities, support subject visits, maintain regulatory documents, and ensure protocol compliance (Correct answer)
To conduct medical assessments and determine subject eligibility
To independently monitor the trial on behalf of the sponsor

Correct answer: To coordinate day-to-day trial activities, support subject visits, maintain regulatory documents, and ensure protocol compliance

The CRC manages the operational aspects of clinical trials including subject coordination, regulatory document maintenance, data collection, and communication with sponsor and IRB.

Question 72: What is a protocol amendment and when is it necessary?

A formal change to the protocol that requires IRB/IEC and regulatory approval before implementation (Correct answer)
An informal note added to the investigator's files
A complete rewrite of the protocol required for every monitoring visit
A correction to the case report form

Correct answer: A formal change to the protocol that requires IRB/IEC and regulatory approval before implementation

A protocol amendment is a written modification to the approved protocol that requires review and approval by the IRB/IEC and, where applicable, the regulatory authority before it can be implemented, unless the change eliminates an immediate safety hazard.

Question 73: What does the term "refresh rate" refer to in a monitor?

The number of pixels on the screen
The time taken to refresh the screen
The brightness of the screen
The number of times per second the display is refreshed (Correct answer)

Correct answer: The number of times per second the display is refreshed

The term 'refresh rate' in a monitor refers to the number of times per second the display is refreshed or updated with new images. Measured in Hertz (Hz), a higher refresh rate results in smoother motion and a more fluid visual experience, especially noticeable in fast-paced videos or gaming. It indicates how quickly the screen can redraw its content.

Question 74: How should the protocol address subject withdrawal and discontinuation?

The protocol must specify criteria for subject withdrawal, procedures for discontinuation, and the type and timing of data to be collected from withdrawn subjects (Correct answer)
Only the informed consent form addresses withdrawal
The protocol does not need to address this topic
Withdrawn subjects are automatically excluded from all analyses

Correct answer: The protocol must specify criteria for subject withdrawal, procedures for discontinuation, and the type and timing of data to be collected from withdrawn subjects

The protocol must describe the criteria that would lead to subject withdrawal, the procedures for orderly discontinuation, and what follow-up data should be collected from withdrawn subjects, including safety follow-up requirements.

Question 75: What must occur before any trial-related procedures are performed on a potential study subject?

The subject must complete all screening assessments
Written informed consent must be obtained (Correct answer)
The site must submit the first enrollment report
The subject must receive the investigational product

Correct answer: Written informed consent must be obtained

ICH-GCP requires that freely given written informed consent must be obtained from each subject before any trial-specific procedures are performed, including screening tests.

Question 76: What is the purpose of a 'randomization log' at a clinical trial site?

To track randomized protocol deviations
To document random audits conducted by the sponsor
To record subjects' random assignment to treatment arms in blinded or open-label trials (Correct answer)
To randomly assign tasks to site staff

Correct answer: To record subjects' random assignment to treatment arms in blinded or open-label trials

A randomization log records each subject's randomization number and treatment assignment (or blind code), maintaining the integrity of the randomization process.

Question 77: In a double-blind, randomized controlled trial, who typically holds the randomization code to protect blinding integrity?

The principal investigator
An unblinded third party such as the sponsor's statistician or an unblinded pharmacist (Correct answer)
The clinical research coordinator
The subject's primary care physician

Correct answer: An unblinded third party such as the sponsor's statistician or an unblinded pharmacist

In double-blind trials, the randomization code is maintained by an unblinded third party so no one at the site can determine treatment assignment.

Question 78: What does 'unexpected' mean when describing an adverse event in a clinical trial?

An event not listed or not consistent with the nature or severity described in the Investigator's Brochure (Correct answer)
An event the investigator was not aware of
An event not previously seen in any patient population
An event that occurs suddenly without warning

Correct answer: An event not listed or not consistent with the nature or severity described in the Investigator's Brochure

'Unexpected' refers to an adverse reaction whose nature, severity, or frequency is not consistent with the information in the Investigator's Brochure or IND.

Question 79: What is the purpose of a close-out visit at the end of a clinical trial?

To ensure all trial activities are completed, documentation is finalized, and site obligations for record retention are communicated (Correct answer)
To file the marketing application
To recruit additional subjects
To conduct the final data analysis

Correct answer: To ensure all trial activities are completed, documentation is finalized, and site obligations for record retention are communicated

The close-out visit (or site termination visit) ensures that all trial-related activities are properly concluded, outstanding data queries are resolved, essential documents are complete, and the site understands its record retention and post-trial responsibilities.

Question 80: What is the GCP requirement for investigator training and qualifications?

Only the PI requires training; subinvestigators do not
A single GCP course completed at any point in the investigator's career is sufficient
Investigators must hold an MD degree only
Investigators must be qualified by education, training, and experience to conduct the specific trial (Correct answer)

Correct answer: Investigators must be qualified by education, training, and experience to conduct the specific trial

GCP requires that investigators be qualified by education, training, and experience, and have access to the resources needed to properly conduct the specific trial.

Question 81: What is the purpose of a 'close-out visit' at the end of a clinical trial?

To conduct the final data monitoring before database lock
To enroll the final subject in the study
To present study results to site staff
To reconcile trial supplies, ensure records are complete, archive documents, and confirm all outstanding issues are resolved (Correct answer)

Correct answer: To reconcile trial supplies, ensure records are complete, archive documents, and confirm all outstanding issues are resolved

The close-out visit ensures all unused drug is reconciled and returned, all essential documents are archived, outstanding data queries are resolved, and the site is properly closed.

Question 82: In clinical data management, what does 'source data' refer to?

Original information in original records and certified copies used as the basis of a clinical trial (Correct answer)
Summarized data in the final study report
Data generated by the CRO
Data entered into the sponsor's database

Correct answer: Original information in original records and certified copies used as the basis of a clinical trial

Source data is the original information first recorded in source documents such as hospital records, clinical charts, lab notes, or diaries.

Question 83: What is the purpose of a Data Safety Monitoring Board (DSMB)?

To manage the trial's financial budget
To independently review accumulating trial data to protect subject safety and trial integrity (Correct answer)
To train site staff on data entry procedures
To audit the sponsor's data management systems

Correct answer: To independently review accumulating trial data to protect subject safety and trial integrity

A DSMB is an independent committee that periodically reviews accumulating data to assess safety, efficacy, and trial conduct, with authority to recommend stopping the trial.

Question 84: In a randomized controlled trial (RCT) study protocol, what is the purpose of randomization?

To minimize selection bias and ensure comparability between groups (Correct answer)
To eliminate the need for control groups
To increase study costs
To assign participants to groups based on preferences

Correct answer: To minimize selection bias and ensure comparability between groups

In a Randomized Controlled Trial (RCT), randomization ensures that participants have an equal chance of being assigned to either the experimental or control group. This process helps to distribute known and unknown confounding factors evenly between groups, minimizing selection bias. As a result, the groups become comparable, allowing any observed differences in outcomes to be confidently attributed to the intervention.

Question 85: What is the significance of maintaining an 'audit trail' for GCP compliance?

It allows reconstruction of study events and demonstrates data integrity to regulators (Correct answer)
It tracks staff training completion
It documents IRB meeting minutes
It satisfies financial reporting requirements

Correct answer: It allows reconstruction of study events and demonstrates data integrity to regulators

An audit trail enables reconstruction of the course of study events and demonstrates to regulators that data were not altered inappropriately, supporting GCP compliance.

Question 86: Which of the following is a key characteristic of good documentation?

Informal and unstructured
Vague and open to interpretation
Clear, concise, and accurate (Correct answer)
Written in technical jargon

Correct answer: Clear, concise, and accurate

Good documentation is characterized by being clear, concise, and accurate. Clarity ensures that the information is easily understood by anyone who reads it, conciseness means it avoids unnecessary jargon or verbosity, and accuracy guarantees that the information is truthful and free from errors. These qualities make documentation reliable and effective for its intended purpose.

Question 87: Which regulatory body must approve a new drug's IND before Phase 1 clinical trials can begin in the US?

IRB
DEA
FDA (Correct answer)
NIH

Correct answer: FDA

The FDA must receive and approve (or allow 30 days to pass without clinical hold) an IND before Phase 1 trials can begin in the US.

Question 88: A participant in a clinical trial is hospitalized for a condition the investigator believes is related to the study drug. What should the investigator do first?

Report the SAE to the sponsor immediately or per the protocol timeline (Correct answer)
Wait until the hospitalization resolves to report
Remove the subject from the study before reporting
Only document the event in the subject's medical record

Correct answer: Report the SAE to the sponsor immediately or per the protocol timeline

Investigators must report SAEs to the sponsor immediately or within the timeframe specified in the protocol, regardless of whether the hospitalization has resolved.

Question 89: A temperature excursion is detected in the IP storage refrigerator over a weekend. What is the appropriate FIRST action?

Dispose of all affected IP immediately
Quarantine the affected IP and notify the sponsor (Correct answer)
Return the IP to the subject and document the event
Continue using the IP and document the excursion in the deviation log

Correct answer: Quarantine the affected IP and notify the sponsor

Affected IP must be quarantined and the sponsor notified so the sponsor can assess whether the product remains suitable for use.

Question 90: When a significant new finding arises during a clinical trial that could affect a subject's willingness to continue, what action is required?

The finding should be reported only to the sponsor
No action is needed until the trial ends
The subject must be informed promptly and re-consent must be obtained with a revised consent form (Correct answer)
Only new subjects need to be informed

Correct answer: The subject must be informed promptly and re-consent must be obtained with a revised consent form

ICH-GCP Section 4.8.2 requires that when new information becomes available that may be relevant to the subject's willingness to continue, the subject must be informed in a timely manner and a revised consent form must be signed.

Question 91: What is the purpose of inclusion and exclusion criteria in a clinical trial protocol?

To simplify the randomization process
To reduce the sponsor's liability
To define the population that can safely and appropriately participate to ensure valid and generalizable results (Correct answer)
To limit the trial to a specific geographic region

Correct answer: To define the population that can safely and appropriately participate to ensure valid and generalizable results

Inclusion and exclusion criteria define the specific characteristics that subjects must have (inclusion) or must not have (exclusion) to participate, ensuring subject safety and producing scientifically valid, interpretable results.

Question 92: What information must be included in a monitoring visit report?

A complete copy of all source documents reviewed
Only deviations and corrective actions
Only a summary of the number of subjects enrolled
The date, site, monitor's name, findings, deviations noted, follow-up actions required, and a summary of key activities performed (Correct answer)

Correct answer: The date, site, monitor's name, findings, deviations noted, follow-up actions required, and a summary of key activities performed

ICH-GCP requires that the monitor provide a written report after each site visit that includes the date, site identification, monitor's name, key findings, deviations observed, corrective actions required, and a summary of review activities performed.

Question 93: What is the difference between an 'adverse event' (AE) and an 'adverse drug reaction' (ADR)?

An ADR is more severe than an AE
An AE only applies to approved drugs
There is no difference
An AE is any untoward event; an ADR implies a causal relationship to the investigational product (Correct answer)

Correct answer: An AE is any untoward event; an ADR implies a causal relationship to the investigational product

An AE is any untoward occurrence regardless of causality, while an ADR implies at least a reasonable causal relationship to the investigational medicinal product.

Question 94: What is 'source document verification' (SDV) and why is it important?

The process of comparing CRF data to source documents to confirm accuracy and completeness of reported data (Correct answer)
Verifying that the IRB reviewed source documents
Verification that source documents are properly archived
Checking that source documents are signed by the subject

Correct answer: The process of comparing CRF data to source documents to confirm accuracy and completeness of reported data

SDV involves comparing data recorded in the CRF against the original source documents to verify accuracy, completeness, and consistency of trial data.

Question 95: What is the monitor's role in managing Corrective and Preventive Actions (CAPAs) at a trial site?

Monitors only document CAPAs without follow-up
The monitor identifies issues, recommends corrective actions, verifies implementation, and follows up to prevent recurrence (Correct answer)
Monitors have no role in CAPAs
CAPAs are exclusively handled by the quality assurance department

Correct answer: The monitor identifies issues, recommends corrective actions, verifies implementation, and follows up to prevent recurrence

Monitors play an active role in the CAPA process by identifying compliance issues during visits, collaborating with the site to develop corrective actions, verifying implementation during subsequent visits, and confirming that preventive measures are effective.

Question 96: What is the purpose of a delegation log in a clinical trial?

To list all regulatory submissions
To track monitoring visit dates
To record all protocol amendments
To document the study staff authorized to perform specific trial-related duties (Correct answer)

Correct answer: To document the study staff authorized to perform specific trial-related duties

The delegation log (also called the delegation of authority log) identifies all persons authorized by the principal investigator to perform significant trial-related duties and specifies those duties.

Question 97: What does 'SUSAR' stand for in clinical research?

Suspected Unexpected Serious Adverse Reaction (Correct answer)
Subject Under Safety Adverse Review
Sponsor Unreported Safety Adverse Report
Serious Unexpected Study Adverse Reaction

Correct answer: Suspected Unexpected Serious Adverse Reaction

SUSAR stands for Suspected Unexpected Serious Adverse Reaction — a serious adverse reaction that is unexpected and for which there is a reasonable causal relationship to the study drug.

Question 98: What is risk-based monitoring (RBM) and why was it introduced in ICH-GCP E6(R2)?

A monitoring approach used only for Phase I trials
An approach that focuses monitoring resources on critical data points and processes most likely to affect subject safety and data integrity (Correct answer)
A cost-cutting measure that reduces monitor training requirements
A method that eliminates all on-site monitoring

Correct answer: An approach that focuses monitoring resources on critical data points and processes most likely to affect subject safety and data integrity

Risk-based monitoring focuses monitoring efforts on the most critical aspects of trial conduct. It was introduced in the E6(R2) addendum to improve monitoring effectiveness and efficiency by directing resources to areas of greatest risk to subject protection and data reliability.

Question 99: Which of the following is a common part of a clinical trial study protocol?

Plans for publishing results
Marketing strategies for the treatment
Ethical considerations and informed consent (Correct answer)
Details of unrelated studies

Correct answer: Ethical considerations and informed consent

Clinical trial protocols are legally and ethically mandated to prioritize the safety and rights of human subjects. They detail the process of obtaining informed consent, ensuring participants fully understand the study's risks and benefits. These ethical considerations and safeguards are crucial for protecting participant well-being throughout the trial.

Question 100: What does 'data reconciliation' involve in clinical trials?

Reconciling the trial budget with actual expenses
Matching subject consent forms to enrollment logs
Resolving discrepancies between different databases such as CRF data and safety databases (Correct answer)
Comparing site-level data to national averages

Correct answer: Resolving discrepancies between different databases such as CRF data and safety databases

Data reconciliation involves comparing and resolving discrepancies between two or more data sources, such as the clinical database and safety or lab databases.

Question 101: What does 'regulatory binder' typically contain at a clinical research site?

Essential documents required by ICH GCP and FDA regulations (Correct answer)
Patient enrollment logs only
Sponsor invoices and budget agreements
Lab results and patient diaries

Correct answer: Essential documents required by ICH GCP and FDA regulations

The regulatory binder contains essential documents such as the protocol, IND, IRB approvals, CVs, lab certifications, and FDA 1572 required by GCP.

Question 102: What is the difference between a primary endpoint and a secondary endpoint in a clinical trial protocol?

There is no meaningful difference
Secondary endpoints are more important than primary endpoints
The primary endpoint is the main outcome measure on which the sample size is based, while secondary endpoints provide supportive evidence (Correct answer)
Primary endpoints are measured first chronologically

Correct answer: The primary endpoint is the main outcome measure on which the sample size is based, while secondary endpoints provide supportive evidence

The primary endpoint is the principal outcome measure that the trial is powered to evaluate and forms the basis for the sample size calculation, while secondary endpoints provide additional supportive or exploratory evidence about the treatment's effects.

Question 103: In what circumstances can informed consent be waived?

In cases of emergency where immediate treatment is required (Correct answer)
If the patient disagrees with the doctor's recommendation
If the patient is nervous about the procedure
If the patient does not speak English

Correct answer: In cases of emergency where immediate treatment is required

Informed consent can be waived in specific, limited circumstances, most notably in cases of emergency where immediate treatment is required to save a life or prevent serious harm. In such situations, obtaining full informed consent might be impractical or impossible, and the principle of implied consent or necessity takes precedence. This waiver is typically governed by strict ethical and legal guidelines.

Question 104: What is a 'monitoring visit report' and who receives it?

A summary of adverse events sent to the FDA
A financial report sent to the CRO by the site
A written record prepared by the monitor after each visit, sent to the sponsor, documenting findings and action items (Correct answer)
A report submitted by the site to the IRB after each visit

Correct answer: A written record prepared by the monitor after each visit, sent to the sponsor, documenting findings and action items

The monitoring visit report documents all findings, observations, and required action items from the visit and is sent to the sponsor and trial master file.

Question 105: In an emergency situation where a subject cannot give consent and no LAR is available, what does ICH-GCP recommend?

The subject cannot be enrolled under any circumstances
The sponsor can provide verbal consent
The subject may be enrolled if the protocol has IRB/IEC-approved provisions for emergency consent exception (Correct answer)
The site coordinator can sign on behalf of the subject

Correct answer: The subject may be enrolled if the protocol has IRB/IEC-approved provisions for emergency consent exception

ICH-GCP Section 4.8.15 allows enrollment without prior consent in emergency situations if the protocol and IRB/IEC-approved procedures provide for such exceptions, and consent is obtained as soon as possible.

Question 106: When an investigational product shipment is received at a clinical site, what is the FIRST action the site should take?

Destroy the outer packaging
Notify the IRB of shipment receipt
Begin dispensing immediately to enrolled subjects
Inspect and document the shipment against the packing slip and protocol requirements (Correct answer)

Correct answer: Inspect and document the shipment against the packing slip and protocol requirements

Upon receipt, the site must inspect the shipment for condition, quantity, and storage compliance and document findings against the packing slip.

Question 107: What is a 'screening failure' in clinical research?

A potential participant who was screened but did not meet eligibility criteria and was not enrolled (Correct answer)
A subject who withdraws before completing the study
A failure in the screening equipment at the site
A protocol violation during the screening visit

Correct answer: A potential participant who was screened but did not meet eligibility criteria and was not enrolled

A screening failure is a subject who was consented and screened for a trial but did not qualify for enrollment based on inclusion/exclusion criteria.

Question 108: What information must the protocol provide about concomitant medications?

Only medications that the investigator personally prescribes
A list of permitted, prohibited, and restricted concomitant medications along with guidelines for managing drug interactions (Correct answer)
A complete pharmacopoeia listing all available drugs
Only the name of the investigational product

Correct answer: A list of permitted, prohibited, and restricted concomitant medications along with guidelines for managing drug interactions

The protocol must specify which concomitant medications and treatments are permitted, restricted, or prohibited during the trial, along with instructions for managing subjects who require prohibited medications.

Question 109: Which of the following best describes 'blinded' investigational product in a randomized controlled trial?

IP stored in a dark environment to prevent photodegradation
IP where the identity of active drug versus placebo is concealed from participants and/or investigators (Correct answer)
IP that has been destroyed and is no longer usable
IP that has failed quality control testing

Correct answer: IP where the identity of active drug versus placebo is concealed from participants and/or investigators

In blinded trials, the identity of the investigational product (active versus placebo) is concealed to reduce bias in the conduct and evaluation of the trial.

Question 110: How should the informed consent process be handled for a subject who cannot read?

A family member can sign without the subject's involvement
The investigator may waive the consent requirement
An impartial witness must be present during the entire consent discussion and must sign the consent form (Correct answer)
The subject cannot participate in clinical trials

Correct answer: An impartial witness must be present during the entire consent discussion and must sign the consent form

When a subject cannot read, ICH-GCP requires that an impartial witness be present during the entire informed consent discussion. The witness must sign and date the consent form to attest that the information was accurately explained and apparently understood.

Question 111: What is a 'corrective and preventive action' (CAPA) plan in clinical trial site management?

A plan to correct subject dosing errors retroactively
A financial correction plan for budget overruns
An emergency response plan for adverse events
A documented plan to address identified deficiencies and prevent their recurrence (Correct answer)

Correct answer: A documented plan to address identified deficiencies and prevent their recurrence

A CAPA plan documents the root cause of identified deficiencies, corrective actions to fix current issues, and preventive measures to stop recurrence.

Question 112: What is the purpose of a certificate of analysis (CoA) for the investigational product?

To certify that the product batch meets predetermined quality specifications (Correct answer)
To confirm the product's marketing authorization
To authorize the site pharmacy to dispense medication
To document patient administration records

Correct answer: To certify that the product batch meets predetermined quality specifications

A Certificate of Analysis certifies that a specific batch of investigational product has been tested and meets all predetermined quality specifications, including identity, purity, potency, and other quality attributes.

Question 113: What is a 'data management plan' (DMP) in clinical research?

A document describing how study data will be collected, managed, validated, and archived (Correct answer)
The IRB's plan for reviewing data safety reports
A site's schedule for data entry
The sponsor's plan for drug distribution

Correct answer: A document describing how study data will be collected, managed, validated, and archived

A data management plan describes the processes, responsibilities, and systems for collecting, handling, validating, and archiving clinical trial data throughout the study.

Question 114: Which type of documentation is typically used in software development to explain the function of a program?

Code comments (Correct answer)
User manuals
Financial reports
Legal documentation

Correct answer: Code comments

Code comments are explanatory notes embedded directly within a program's source code. They are essential for developers to understand the logic, purpose, and functionality of different parts of the code. This practice significantly improves code readability, maintainability, and collaboration among development teams.

Question 115: Which ICH guideline defines Good Clinical Practice (GCP) standards internationally?

ICH E3
ICH E9
ICH E10
ICH E6 (Correct answer)

Correct answer: ICH E6

ICH E6 (R2) is the international GCP guideline that establishes standards for the design, conduct, and reporting of clinical trials.

Question 116: What must a site do if the Principal Investigator leaves during an ongoing clinical trial?

Withdraw all enrolled subjects from the study
Immediately halt all subject visits and data collection
Continue the study under the existing sub-investigator without notifying anyone
Notify the sponsor and IRB, arrange for a qualified replacement PI, and obtain necessary approvals before continuing (Correct answer)

Correct answer: Notify the sponsor and IRB, arrange for a qualified replacement PI, and obtain necessary approvals before continuing

An investigator change requires notifying the sponsor and IRB, submitting updated regulatory documents for the replacement PI, and receiving approval before the new PI assumes responsibility.

Question 117: What is the purpose of collecting 'concomitant medications' data during a clinical trial?

To ensure subjects follow the prescribed dosing schedule
To track healthcare utilization costs
To assess potential drug interactions and confounding effects on safety and efficacy outcomes (Correct answer)
To meet billing and reimbursement requirements

Correct answer: To assess potential drug interactions and confounding effects on safety and efficacy outcomes

Collecting concomitant medication data allows detection of potential drug-drug interactions that could confound efficacy results or contribute to observed adverse events.

Question 118: What is the 'audit trail' requirement under 21 CFR Part 11?

A record of all subject visits
A financial record of trial expenses
A log of all adverse events
A computer-generated, time-stamped record of who created, modified, or deleted electronic data (Correct answer)

Correct answer: A computer-generated, time-stamped record of who created, modified, or deleted electronic data

An audit trail is a secure, computer-generated, time-stamped record that independently logs operator entries and actions to reconstruct the course of events.

Question 119: The Belmont Report established which three fundamental ethical principles for research with human subjects?

Consent, Privacy, Accountability
Safety, Efficacy, Quality
Autonomy, Beneficence, Non-Maleficence
Respect for Persons, Beneficence, Justice (Correct answer)

Correct answer: Respect for Persons, Beneficence, Justice

The Belmont Report (1979) established Respect for Persons, Beneficence, and Justice as the three core ethical principles for human subjects research.

Question 120: How long must essential clinical trial documents typically be retained after the formal discontinuation of a drug's clinical development?

At least 5 years
At least 15 years
At least 2 years (Correct answer)
1 year

Correct answer: At least 2 years

ICH-GCP guidelines state that essential documents should be retained for at least 2 years after the last approval of a marketing application or after formal discontinuation of clinical development of the investigational product.

Question 121: What is the primary purpose of documentation in a professional setting?

To reduce the workload
To ensure that employees work faster
To provide evidence of work completed (Correct answer)
To eliminate the need for verbal communication

Correct answer: To provide evidence of work completed

The primary purpose of documentation in a professional setting is to provide verifiable evidence of work completed, decisions made, and processes followed. This ensures accountability, transparency, and traceability, which are crucial for compliance, audits, legal protection, and effective communication among team members. It creates a reliable record of activities.

Question 122: What is the purpose of investigational product reconciliation at the end of a clinical trial?

To prepare unused IP for future commercial marketing
To confirm that IP costs were within the contracted study budget
To determine the residual commercial value of remaining IP
To verify that all IP received, dispensed, and returned or destroyed is fully accounted for (Correct answer)

Correct answer: To verify that all IP received, dispensed, and returned or destroyed is fully accounted for

IP reconciliation at study close-out ensures that every unit of investigational product is fully accounted for from receipt through final disposition.

Question 123: According to FDA regulations, which of the following is NOT required on a Form FDA 1572?

The investigator's financial disclosure information (Correct answer)
Commitment to follow GCP
Location of the study site
Names of subinvestigators

Correct answer: The investigator's financial disclosure information

Financial disclosure is collected on Form FDA 3455/3454, not on Form FDA 1572, which covers investigator commitments and site information.

Question 124: What is an 'expedited report' as opposed to a 'periodic report' for adverse events?

They are the same report submitted on different schedules
Expedited reports are required within days for unexpected SAEs; periodic reports (e.g., annual reports) summarize all safety data (Correct answer)
Expedited reports cover all AEs; periodic reports cover only SAEs
Expedited reports are submitted by the IRB; periodic reports by the sponsor

Correct answer: Expedited reports are required within days for unexpected SAEs; periodic reports (e.g., annual reports) summarize all safety data

Expedited reports (7 or 15 days) are required for unexpected serious adverse reactions, while periodic safety reports summarize all accumulated safety data on a scheduled basis.

Question 125: What is database lock in a clinical trial?

A regulatory hold placed on a database by FDA
Archiving old study databases
The process of finalizing the clinical database after all data issues are resolved, preventing further changes (Correct answer)
Encrypting the database to prevent hacking

Correct answer: The process of finalizing the clinical database after all data issues are resolved, preventing further changes

Database lock is the final step in data management where all queries are resolved and the database is locked against further changes before statistical analysis.

Question 126: When must a protocol deviation be documented and reported to the IRB/IEC?

Only during scheduled monitoring visits
Only if it results in a serious adverse event
Promptly, in accordance with the IRB/IEC's reporting requirements (Correct answer)
Only at the end of the study

Correct answer: Promptly, in accordance with the IRB/IEC's reporting requirements

Protocol deviations must be documented and reported to the IRB/IEC promptly according to their specific reporting requirements. Many IRBs require reporting within a defined timeframe, especially for deviations that may affect subject safety or data integrity.

Question 127: Who is primarily responsible for maintaining investigational product accountability records at a clinical trial site?

The sponsor's monitor
The principal investigator or designee (Correct answer)
The site's pharmacy regulatory board
The IRB/IEC

Correct answer: The principal investigator or designee

Under ICH GCP E6(R2), the principal investigator or their designee is responsible for maintaining accurate IP accountability records at the site.

Question 128: What is the investigator's responsibility regarding subjects who withdraw their consent during a clinical trial?

Continue collecting data without the subject's knowledge
Exclude all previously collected data from the analysis
Report the withdrawal as a protocol violation
Respect the withdrawal, discontinue trial procedures, and offer the option to allow use of already-collected data (Correct answer)

Correct answer: Respect the withdrawal, discontinue trial procedures, and offer the option to allow use of already-collected data

When a subject withdraws consent, the investigator must respect the decision, stop trial procedures, and may ask whether the subject agrees to allow continued use of data already collected, but cannot compel it.

Question 129: A subject accidentally takes double their prescribed dose of investigational product. What must the site do?

Document the error as a protocol deviation, assess for adverse effects, and report per protocol (Correct answer)
Report this only in the final clinical study report
Disregard the event if no symptoms are observed
Immediately withdraw the subject without documentation

Correct answer: Document the error as a protocol deviation, assess for adverse effects, and report per protocol

Medication errors must be documented as protocol deviations, the subject assessed for adverse effects, and events reported per protocol and regulatory requirements.

Question 130: What is the role of a 'Legally Authorized Representative' (LAR) in clinical research?

A sponsor's legal counsel
An FDA inspector authorized to audit a site
An individual or body authorized to consent on behalf of a prospective subject who cannot provide their own consent (Correct answer)
A CRO with authority to sign contracts

Correct answer: An individual or body authorized to consent on behalf of a prospective subject who cannot provide their own consent

An LAR is a person or entity permitted under applicable law to consent on behalf of a prospective subject who lacks decision-making capacity.

SOCRA CCRP Certification Exam

The SOCRA Certified Clinical Research Professional (CCRP) exam validates knowledge and competency in clinical research operations, covering study start-up, implementation, and closure in accordance with ICH-GCP guidelines and regulatory requirements.

130

Questions

240 min

Time Limit

71%

To Pass

Checking for saved progress...

Exam Rules

You can skip questions and return to them later
Flag questions for review before submitting
No feedback shown until you submit the entire exam
Unanswered questions count as wrong — answer everything
10 pretest questions are mixed in and don't affect your score
Timer auto-submits when time runs out
Your progress is auto-saved every 30 seconds

These practice questions were written with AI tools. They are not real exam questions. Exam facts are checked against the official sources listed below. Not reviewed by a subject-matter expert. Editorial policy

Sources & references

Exam facts on this page (fees, format, dates, passing scores) are checked against these official sources; the date is our last check. Editorial policy

socra.org — Exam format, passing score, score validity, test delivery, registration deadline, test dates, time limit, retake fee, eligibility, fees · verified Oct 2026
prometric.com — Test delivery · verified Oct 2026